Allspring Global Investments Holdings LLC Trims Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Allspring Global Investments Holdings LLC trimmed its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 40.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,263 shares of the company’s stock after selling 16,683 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Amphastar Pharmaceuticals were worth $1,177,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. GAMMA Investing LLC boosted its stake in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares during the period. Innealta Capital LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the second quarter valued at about $55,000. Blue Trust Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after buying an additional 309 shares during the period. nVerses Capital LLC grew its holdings in shares of Amphastar Pharmaceuticals by 37.5% during the second quarter. nVerses Capital LLC now owns 2,200 shares of the company’s stock worth $88,000 after buying an additional 600 shares during the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new position in Amphastar Pharmaceuticals in the 2nd quarter valued at about $93,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 17,101 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the sale, the director now directly owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 17,101 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the transaction, the director now owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the sale, the director now owns 75,409 shares in the company, valued at $3,504,256.23. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,101 shares of company stock worth $1,069,350. 27.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AMPH. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, October 18th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $63.00.

Amphastar Pharmaceuticals Price Performance

NASDAQ AMPH opened at $50.53 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of 17.48, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83. The company has a 50 day simple moving average of $48.17 and a 200-day simple moving average of $43.72. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. The firm had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Equities research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.